Skip to content
All resources

Foundations

Health Canada's Unauthorized Semaglutide and GLP-1 Warnings, Explained

AR

By

· 9 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. What did the January 2026 advisory say?
  2. What other warnings and recalls cover GLP-1 drugs?
  3. How can a counterfeit carry a DIN?
  4. How do you check a DIN in the Drug Product Database?
  5. What has testing of unauthorized semaglutide found?
  6. How does research-reagent supply relate to these warnings?
  7. Where should a concern be reported?
  8. Frequently asked questions

Health Canada has published several warnings about unauthorized and counterfeit GLP-1 drugs. The main one, a January 2026 public advisory, tells Canadians to buy semaglutide and tirzepatide only from licensed pharmacies, and to confirm the eight-digit DIN in the Drug Product Database. Other notices cover counterfeit Mounjaro pens carrying an invalid DIN, sellers of unauthorized peptides including tirzepatide and retatrutide, and a compounded semaglutide product made from an unauthorized ingredient. This page summarises what each one says.

A printed public health advisory with a red warning band on a desk, beside a plain sealed carton and a magnifying glass
Illustration: a health advisory, read closely.

What did the January 2026 advisory say?

The advisory, "Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products" (RA-81518), was published on 21 January 2026. Its main points:

  • The products. Unauthorized and counterfeit versions of GLP-1 receptor agonists, sold in stores and online. Health Canada said it had found "various retailers in Canada" selling them.
  • Fake endorsements. Some websites and social media advertisements used Health Canada's logo or showed fake endorsements. Health Canada states that it never endorses a health product and does not allow its logo to be used on health product advertising or packaging.
  • The risks it lists. Too much, too little or none of the active ingredient; unlisted or unknown ingredients; contaminants such as solvents, heavy metals, particles or microbes; poor labelling; and improper manufacture or storage.
  • What it tells people to do. Buy prescription drugs only from a licensed pharmacy, check for the DIN and search it in the Drug Product Database, and report suspected counterfeit or unauthorized products to Health Canada.
  • Enforcement. Health Canada said it was monitoring the market, seizing products, issuing compliance and warning letters, and working with the Canada Border Services Agency to stop shipments entering Canada.

The advisory also states which products are legitimate, and how Health Canada regulates drugs explains what that authorisation consists of. Semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescription drugs that Health Canada has authorised to treat type 2 diabetes and obesity. Health Canada's own warning is the clearest evidence that the molecules are not the problem. The problem is products sold outside the authorised supply chain.

What other warnings and recalls cover GLP-1 drugs?

Search Health Canada's recalls and safety alerts database (recalls-rappels.canada.ca) for semaglutide, tirzepatide or GLP-1 and you get three different kinds of notice. It helps to keep them apart.

Kind of noticeExampleWhat it means
Public advisory about unauthorized productsJanuary 2026 GLP-1 advisory; April 2026 peptides advisory naming retatrutideProducts with no authorisation are on sale; do not buy or use them
Advisory about counterfeitsMarch 2026: counterfeit Mounjaro vials and pens seized at a Mississauga businessProducts made to look like an authorised drug, sometimes with a DIN printed on them
Recall of an authorised productAugust 2026: an authorised semaglutide product, recalled because one impurity was out of specification in the affected lotsA real, authorised drug with a quality defect in specific lots
Recall of a compounded productJanuary 2025: a compounded semaglutide and pyridoxine product made with an unauthorized active pharmaceutical ingredientA pharmacy preparation whose ingredient was not authorised

The recalls are evidence that the system works, not that it fails. When an authorised product has a problem, the manufacturer recalls particular lots by DIN and lot number, and the notice says which ones. An unauthorized product has no DIN and no lot traceability to a reviewed specification, so there is often nothing to recall. Health Canada can only warn people and seize what it finds.

The compounded row deserves a note of its own, because compounding is a legitimate pharmacy practice with its own rules. The concern with GLP-1 compounding has mostly been documented in the United States. A review of the FDA adverse event reporting database found that reports involving compounded GLP-1 drugs were much more likely than reports for the authorised products to mention preparation errors, contamination and manufacturing issues (PMID 40285721). A poison-centre case series described measurement errors when compounded semaglutide was supplied in vials with general-purpose syringes rather than in the manufacturer's pens (PMID 37392810). Neither finding is about Canadian pharmacies specifically.

How can a counterfeit carry a DIN?

The March 2026 advisory shows how. Health Canada reported counterfeit Mounjaro vials and KwikPens seized at a business in Mississauga. Some carried a DIN that Health Canada called invalid, along with a batch number that was also invalid. The manufacturer confirmed the products were counterfeit. Printing a number on a box costs nothing, so a DIN on a label does not prove a product is authorised, any more than a purity figure on a label proves what is in the vial, a point what a certificate of analysis establishes makes about documents generally. The check is whether that DIN, searched in the Drug Product Database, returns the product, manufacturer, strength and form you are holding.

How do you check a DIN in the Drug Product Database?

The database is free and public. To check a product:

  1. Search by DIN if the label has one. A valid result shows the brand name, the company, the active ingredient and strength, the dosage form and whether the product is marketed.
  2. Compare every field with the package. A real DIN copied onto a fake package will return a product, but the strength, form or company may not match.
  3. Search by ingredient if there is no DIN. If no authorised product with that ingredient exists, nothing sold under that name in Canada is authorised.
  4. Read the status. The database separates marketed, approved, dormant and cancelled products. A cancelled DIN is not a current authorisation.

The online search was down for maintenance when this page was written. Health Canada also publishes the database as a downloadable data extract for anyone who needs to search it in bulk. Generic semaglutide in Canada explains why a product marketed as "generic" still needs its own authorisation and DIN.

What has testing of unauthorized semaglutide found?

The best published test purchase comes from Hungary. Researchers bought semaglutide from illegal online pharmacies that sold it without a prescription. Three vials arrived, and the three prefilled pens ordered never did, which the authors described as non-delivery scams. All three vials were judged probably substandard or falsified. The semaglutide content was 29 to 39 percent above the labelled amount. Endotoxin was detected in every vial. And the measured semaglutide purity was between 7.7 and 14.4 percent, against the figure printed on the labels (PMID 39509151).

Reports of harm have also been collected. An analysis of the European pharmacovigilance database found 234 case reports linked to potentially counterfeit semaglutide between 2018 and 2025. Most were classed as serious. Compared with authentic semaglutide, low blood sugar and "drug ineffective" were reported disproportionately often (PMID 42137313). Reporting databases cannot show how often harm occurs, only what kinds get reported. Gray-market retatrutide explains why trial results for a drug do not carry over to an unregulated product with the same name.

How does research-reagent supply relate to these warnings?

There is no clean line, and it would be misleading to draw one. Health Canada's April 2026 advisory names retatrutide among the unauthorized peptides it has seized. It says products marketed as "For Research Use Only – Not for Human Consumption" are not made legal or exempt by that label, and it tells consumers not to buy or use them. Its peptides research page says a research use label "does not make a product legal to import or sell in Canada." Several earlier advisories named sellers with "Research" in their names.

The differences that do exist are differences of claim and purpose, not legal exemptions. A pharmacy-dispensed GLP-1 drug is an authorised medicine for a patient. A counterfeit pretends to be that medicine. A research reagent is supplied as a laboratory chemical, with no authorisation for human use and no claim that it is equivalent to an authorised drug. Health Canada's position is that the third category is still covered by the Food and Drugs Act and still subject to enforcement. Research use only: what the label means covers what the label does and does not do, and compounded versus research peptides covers the pharmacy route. Material supplied as a research reagent, tirzepatide included, is not an authorised drug and must not be used as one.

Where should a concern be reported?

Each advisory tells the reader to report side effects and complaints to Health Canada, including suspected counterfeit or unauthorized products, and to speak to a healthcare professional about any health concern. Health Canada's drugs and health products portal links to both reporting forms.

Nothing here is medical, dosing, or therapeutic guidance.

Frequently asked questions

Is semaglutide authorised in Canada? Yes, as specific prescription products. Health Canada's January 2026 advisory names Ozempic, Rybelsus and Wegovy, and the Drug Product Database lists semaglutide products from more than one company. The authorisation belongs to each product with its DIN. It does not extend to any other preparation of the same molecule.

What does a Health Canada public advisory mean? It is a public warning about a health risk, often listing products or sellers. It is different from a recall, which is a company taking back specific lots, usually of an authorised product. An advisory about unauthorized products often comes alongside seizures, warning letters or orders to stop selling.

Can a counterfeit GLP-1 pen have a real-looking DIN? Yes. Health Canada's March 2026 advisory described counterfeit Mounjaro pens with a DIN and batch number that were both invalid. The manufacturer confirmed they were fake. Search the DIN in the Drug Product Database and check that the brand, company, strength and form all match the package.

Is tirzepatide authorised in Canada? Yes. Health Canada lists it as a prescription drug sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Its advisories also describe counterfeit and unauthorized tirzepatide products seized in Canada, so check the DIN rather than relying on the name.

Has Health Canada warned about retatrutide? Yes. Retatrutide appears on the list of unauthorized peptides in Health Canada's April 2026 advisory, and in lists of products seized from sellers in 2025. Retatrutide is an investigational drug that no regulator has approved. Health Canada's peptide pages say that people in Canada can receive unauthorized peptides as enrolled participants in an approved clinical trial.

Selected Research References

  1. Ashraf AR, Mackey TK, Vida RG, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research. 2024;26:e65440. pubmed.ncbi.nlm.nih.gov/39509151
  2. Zinzi A, Gaio M, Ruggiero R, et al. Unmasking counterfeit semaglutide: analysis of real-world safety data from EudraVigilance. Frontiers in Pharmacology. 2026;17:1805842. pubmed.ncbi.nlm.nih.gov/42137313
  3. McCall KL, Mastro Dwyer KA, Casey RT, et al. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. Expert Opinion on Drug Safety. 2026;25(3):581-588. pubmed.ncbi.nlm.nih.gov/40285721
  4. Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center-Case series. Journal of the American Pharmacists Association. 2023;63(5):1643-1645. pubmed.ncbi.nlm.nih.gov/37392810

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.